Suppr超能文献

伏立康唑所致幻听:通过血浆监测说明

[Auditory hallucinations due to voriconazole: Illustration by plasma monitoring].

作者信息

Gaïes E, Jebabli N, Salouage I, Trabelsi S, Charfi R, Lakhal M, Klouz A

机构信息

Service de pharmacologie clinique, centre national de pharmacovigilance de Tunis, 9, avenue Dr. Zouheir-Essafi, 1006 Tunis, Tunisie.

出版信息

J Mycol Med. 2011 Sep;21(3):214-6. doi: 10.1016/j.mycmed.2011.06.002. Epub 2011 Jul 20.

Abstract

Voriconazole is a second-generation azole antifungal that is widely indicated in the treatment of invasive aspergillosis. It is generally well tolerated. It has nevertheless numerous side effects like hepatotoxicity, photosensitivity, skin rashes, and visual disturbances. Hallucinations were also reported as side effects to voriconazole but auditory hallucinations were rarely reported and seem to be related to toxic voriconazole blood levels. We report, herein, a case of auditory hallucination with monitoring of voriconazole plasma concentration during hallucination and after its disappearance. A 38-year-old man was treated with intravenously voriconazole for a pulmonary aspergillosis. Seven days after the initiation of voriconazole, the patient presented a sudden history of auditory hallucination associated to incoherence and temporo-spatial disorientation. Therapeutic drug monitoring of voriconazole showed a plasmatic residual concentration (C0) of 7.5μg/mL (therapeutic interval: 1.4-1.8μg/mL) and a pic concentration (Cmax) of 9.83μg/mL (therapeutic interval: 2.1-4.8μg/ml). Voriconazole was then stopped and, two days later, symptomatology completely disappeared and at the same time levels of voriconazole decreased (C0=0.11μg/mL and Cmax=2.17μg/mL). We concluded in our case that the patient's auditory hallucinations were caused by voriconazole treatment. In fact, the sudden onset of hallucinations was concomitant with high plasmatic voriconazole levels, and since the medication was stopped, an important decrease of voriconazole levels was observed which was associated with a sudden disappearance of the auditory hallucinations.

摘要

伏立康唑是一种第二代唑类抗真菌药物,广泛用于治疗侵袭性曲霉病。它通常耐受性良好。然而,它有许多副作用,如肝毒性、光敏性、皮疹和视觉障碍。也曾有报道称幻觉是伏立康唑的副作用,但很少有关于幻听的报道,且似乎与伏立康唑的血液中毒水平有关。在此,我们报告一例幻听病例,并在幻觉期间及消失后监测伏立康唑的血浆浓度。一名38岁男性因肺曲霉病接受伏立康唑静脉治疗。伏立康唑治疗开始7天后,患者突然出现幻听,伴有思维不连贯及时空定向障碍。伏立康唑的治疗药物监测显示血浆残留浓度(C0)为7.5μg/mL(治疗区间:1.4 - 1.8μg/mL),峰浓度(Cmax)为9.83μg/mL(治疗区间:2.1 - 4.8μg/ml)。随后停用伏立康唑,两天后,症状完全消失,同时伏立康唑水平下降(C0 = 0.11μg/mL,Cmax = 2.17μg/mL)。我们在该病例中得出结论,患者的幻听是由伏立康唑治疗引起的。事实上,幻觉的突然发作与伏立康唑的高血浆水平同时出现,并且自从停药后,观察到伏立康唑水平显著下降,这与幻听的突然消失相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验